Novarock Biotherapeutics Ltd.
🇺🇸United States
Clinical Trials
4
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (100.0%)A Study of NBL-028 in Patients With Advanced Solid Tumors
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- NovaRock Biotherapeutics, Ltd
- Target Recruit Count
- 270
- Registration Number
- NCT06223256
- Locations
- 🇨🇳
No.896 East Zhongshan Road, Shijiazhuang, Hebei Province, China., Shijiazhuang, Hebei, China
A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.
Phase 1
Recruiting
- Conditions
- Advanced Malignant Tumors
- Interventions
- Drug: NBL-020 for Injection
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- NovaRock Biotherapeutics, Ltd
- Target Recruit Count
- 200
- Registration Number
- NCT05877924
- Locations
- 🇨🇳
Wu Yilong, Guanzhou, Guangdong, China
A Study of NBL-012 in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: NBL-012 InjectionDrug: Placebo
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- NovaRock Biotherapeutics, Ltd
- Target Recruit Count
- 52
- Registration Number
- NCT05259189
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University., Suzhou, Jiangsu, China
Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- NovaRock Biotherapeutics, Ltd
- Target Recruit Count
- 410
- Registration Number
- NCT05153096
- Locations
- 🇨🇳
Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
News
No news found